ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1132

Liver and Kidney Cross-Talk in Korean COVID-19 Patients

Session Information

  • COVID-19 - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Kim, Yae-hyun, Seoul National University Hospital, Jongno-gu, Seoul, Korea (the Republic of)
  • Kim, Yaerim, Keimyung University School of Medicine, Daegu, Korea (the Republic of)
  • Kwon, Soie, Chung Ang University Hospital, Seoul, Korea (the Republic of)
  • Lee, Jeonghwan, Seoul National University Seoul Metropolitan Government Boramae Medical Center, Dongjak-gu, Seoul, Korea (the Republic of)
  • Lee, Jung Pyo, Seoul National University College of Medicine, Seoul, Korea (the Republic of)
Background

Previous studies suggested that liver function tests (LFTs) could serve as a prognostic tool in assessing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. However there have been no published large-scale studies conducted for Koreans with similar topics.

Methods

This research was conducted using the data from two hospitals in Korea. Data from 4,367 adults out of 4,423 patients without missing values, end-stage renal disease, a history of kidney transplant, or use of immunosuppressants were analyzed. We used LFTs measured on the day of hospitalization for SARS-CoV-2 infection. The main outcomes of interest were two things: all-cause mortality and the incidence of acute kidney injury (AKI). Statistical analysis was performed with logistic regression.

Results

Analysis of data for 4,367 people (mean age 54.5±18.3 years, 54.3% female) suggests that high bilirubin is associated with high mortality (adjusted hazard ratio [aHR], 1.794; 95% confidence interval [CI], 1.292 to 2.492; P<0.001) and risk of AKI (aHR, 1.263; 95% CI, 1.005 to 1.588; P=0.045). Also low albumin level is associated with high mortality (aHR, 0.574; 95% CI, 0.378 to 0.873; P<0.001). However no significant impact of alanine transferase and alkaline phosphatase on mortality and the incidence of AKI is identified.

Conclusion

Abnormal LFTs, especially in aspartate transaminase, total bilirubin and albumin level, is relevant to higher mortality and risk of AKI in Koreans with COVID-19. Therefore LFTs should be performed early in hospitalization as a screening tool for risk stratification in Korean COVID-19 patients.

Significance of liver function on all-cause mortality

Significance of liver function on the incidence of AKI